GMED vs. RMD, STE, BAX, HOLX, PODD, TFX, MASI, ITGR, IART, and ATEC
Should you be buying Globus Medical stock or one of its competitors? The main competitors of Globus Medical include ResMed (RMD), STERIS (STE), Baxter International (BAX), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), Masimo (MASI), Integer (ITGR), Integra LifeSciences (IART), and Alphatec (ATEC). These companies are all part of the "health care equipment" industry.
Globus Medical (NYSE:GMED) and ResMed (NYSE:RMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation.
Globus Medical received 132 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 67.87% of users gave Globus Medical an outperform vote while only 52.93% of users gave ResMed an outperform vote.
In the previous week, Globus Medical had 8 more articles in the media than ResMed. MarketBeat recorded 20 mentions for Globus Medical and 12 mentions for ResMed. Globus Medical's average media sentiment score of 1.01 beat ResMed's score of 0.96 indicating that Globus Medical is being referred to more favorably in the media.
ResMed has higher revenue and earnings than Globus Medical. ResMed is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
Globus Medical presently has a consensus price target of $69.40, suggesting a potential upside of 3.41%. ResMed has a consensus price target of $202.80, suggesting a potential downside of 1.71%. Given Globus Medical's higher possible upside, equities analysts clearly believe Globus Medical is more favorable than ResMed.
Globus Medical has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, ResMed has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.
ResMed has a net margin of 20.91% compared to Globus Medical's net margin of 3.51%. ResMed's return on equity of 24.43% beat Globus Medical's return on equity.
95.2% of Globus Medical shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 18.5% of Globus Medical shares are held by insiders. Comparatively, 1.2% of ResMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Globus Medical beats ResMed on 9 of the 17 factors compared between the two stocks.
Get Globus Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Globus Medical Competitors List
Related Companies and Tools
